Read our February issue! Featuring Oropouche virus in Brazil, mosquito-disseminated pyriproxyfen to control dengue, and TB diagnostics in children thelancet.com/journals/lanin…

Trachoma is the leading infectious cause of blindness worldwide. In a new Seminar, Esmael Habtamu & colleagues provide an overview of the key clinical and public health features of trachoma. Explore now ➡️ hubs.li/Q03nWybF0

☀️ On the cover of @TheLancetInfDis June issue in time for European arbovirus season, the @PREPARE_EUROPE MERMAIDS-Arbo doublebill of papers with commentary now in print - thank you! 🦟 Full issue: thelancet.com/journals/lanin… 🤒 Clinical outcomes: thelancet.com/journals/lanin… 🦠 Serology diagnostic algorithm: thelancet.com/journals/lanin… 🗣️ Commentary: thelancet.com/journals/lanin… @louise_sigfrid @LouellaMRK @siyu1000 @MarionKoopmans

In @TheLancetInfDis, MSF highlighted the urgent need for a ring vaccination strategy to curb the cholera outbreak in DRC and neighbouring countries, worsened by ongoing conflict. #Cholera #GlobalHealth #DRC 💉 shorturl.at/2hRzU

A study in @TheLancetInfDis confirmed the safety & efficacy of single low-dose primaquine in reducing malaria transmission in young children & could support global #malaria elimination efforts & limit the spread of drug resistant #malaria iddo.org/news/new-study-conf… @TropMedOxford

While little is known about the mysterious #Oropouche virus in Latin America, a number of deaths have been reported along with impacts on unborn babies. A #CharitéBerlin study has discovered that the pathogen is more widespread than previously thought. charite.de/en/service/press_…

Now, there is a 2024 WHO Bacterial Priority Pathogens List 🆕 An article in @TheLancetInfDis details the processes involved in this important revision ⤵️ bit.ly/3EoCZUG

1/5 🔥 Hot off the press — PAXLC trial results now in @TheLancetInfDis （🇯🇵日本語解説付き） After 3 years of dedicated work, we’re proud to share results from PAX LC: a fully decentralized, double-blind, placebo-controlled, FDA-authorized Phase 2 trial of Paxlovid (nirmatrelvir/ritonavir) for long COVID across 48 U.S. states (NCT05668091) ✅ 100 adults with long COVID ✅ Randomized 1:1 to Paxlovid or placebo (ritonavir only) ✅ 15-day oral treatment 🎯 Primary outcome: Change in PROMIS-29 PHSS at Day 28 from baseline Here’s what we found—and why it matters. 🧵👇 Get your free copy here: sciencedirect.com/science/ar… 1/5 🔥速報：PAX LC 試験の結果が @TheLancetInfDis に掲載されました！ 3年にわたる設計と実施を経て、コロナ後遺症に対するパキロピッドの有効性と安全性を検証した**分散型・二重盲検・プラセボ対照・FDA承認の第2相試験「PAX LC」**の結果を報告します（米国48州対象）。 ✅ コロナ後遺症の成人100名が参加 ✅ パキロピッドまたはプラセボ（リトナビルのみ）に1:1で無作為化 ✅ 経口治療を15日間 🎯 主要評価項目：ベースラインから28日目時点での PROMIS-29 PHSS の変化 ここから、試験結果とその意義を詳しくご紹介します🧵👇 @MitsuakiSawano @bornali_27 @CesarCaraballoC @rohan_khera @jspertus @VirusesImmunity @hmkyale @YaleMed @YaleIMed @YaleCardiology @YaleCII #PAXLC #LongCOVID #RCT #Paxlovid Find our other related materials here: ClinicalTrials.gov : clinicaltrials.gov/study/NCT… PAXLC Design Paper: sciencedirect.com/science/ar… PAXLC Demographics Paper: medrxiv.org/content/10.1101/…

We were so happy to partner with participants on this decentralized, technology-enabled trial. Innovative way to do trials. I just wish the result had been better for patients. @VirusesImmunity @YaleMed @yalediscovers @TheLancetInfDis medicine.yale.edu/news-artic…

We are hiring a Deputy Editor for The Lancet Regional Health – Southeast Asia Find out more about the role here lnkd.in/gBEyCJKB @TheLancet @GKangInd @doctorsoumya @WHOSEARO @AnuragAgrawalMD @swarup1972 @vivekkute @combatstrokeSL @lakshmivijayku1

Out now in @TheLancetInfDis our #SEMVAc study demonstrates that the MVA-BN vaccine (Imvanex/Jynneos) is safe & effective against #mpox, but a single dose does not sufficiently protect people living with #HIV. Thank you @EMA_News for support. thelancet.com/journals/lanin…

RESISTANCE IN TB AND HIV: Article we just wrote for the @TheLancetInfDis on a consequence of HIV global funding cuts that has not been discussed much -the development of drug resistance in HIV and TB thelancet.com/journals/lanin…

RT @SasoGynaecology: Well done to my sister @AnjaSaso on her excellent RCT just published in @TheLancetInfDis looking at effect of #pertuss…

Delighted to share my latest clinical case report published in @TheLancetInfDis from Fudan University, highlighting a case of mistaken identity—sinusitis mimicking meningioma! Thanks to @FadenLab from @MassEyeAndEar @Harvard, the co-first author, for his invaluable guidance

🆕The absence of essential diagnostic & therapeutic tools is a crucial barrier to Zika virus preparedness & response. A @TheLancetInfDis & Lancet Microbe Series outlines a comprehensive strategy to advance research, policy, & investment to address this: hubs.li/Q038m_VF0

Very pleased to share our latest paper in @TheLancetInfDis. This paper considers the complex issues of antimicrobials at the end-of-life, including nonclinical factors that must be navigated in the dying process. Thanks to @BillyRosaPhD for leading this! sciencedirect.com/science/ar…

With cholera resurging in recent years, this letter by @SecGTFCC @TheLancetInfDis highlights the crucial principle of adaptive surveillance. It stresses that surveillance must be tailored to different epidemiological contexts, as outlined in their guidance thelancet.com/journals/lanin…

Cholera has skyrocketed globally in recent years, linked to factors such as conflict, displacement, and climate change. A lack of political commitment & investment in controlling cases has also contributed to its resurgence. Read more in the latest news piece from @TheLancetInfDis ▶️ hubs.li/Q039pBC90

In this editorial in @TheLancetInfDis with @ACasadevall1 , we show how SARS-CoV-2 evolution once again defeated an anti-Spike mAb (#sipavibart / #AZD3152) before it reached the marked. thelancet.com/journals/lanin… @bjarijn @ShohamTxID @jhDavidSullivan @manuelenicastri @hueso_thomas

💊Very happy to share our paper in @TheLancetInfDis on doxypep: hopes and fears for implementation . 😍This is a joint effort with @GilmoreJNurse ; Manik Kohli; @EdFTMxxx ; @benvyle; and Laia Ventura 👉Access here: thelancet.com/journals/lanin…

Europe needs a sustainably funded influenza research and response network - especially in the light of H5N1 and current developments in the US. Read our commentary in The Lancet ID: thelancet.com/journals/lanin… With @wendybarclay11, @MarionKoopmans and many other colleagues.